Article
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
JAMA oncology - 1 Aug 2016
Boekhout Annelies H, Gietema Jourik A, Milojkovic Kerklaan Bojana, van Werkhoven Erik D, Altena Renske, Honkoop Aafke, Los Maartje, Smit Willem M, Nieboer Peter, Smorenburg Carolien H, Mandigers Caroline M P W, van der Wouw Agnes J, Kessels Lonneke, van der Velden Annette W G, Ottevanger Petronella B, Smilde Tineke, de Boer Jaap, van Veldhuisen Dirk J, Kema Ido P, de Vries Elisabeth G E, Schellens Jan H M
Abstract excerpt
IMPORTANCE: This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention of trastuzumab-related cardiotoxic effects. OBJECTIVE: To determine as the primary end point whether angiotensin II antagonist treatment with candesartan can prevent or ameliorate trastuzumab-related cardiotoxic effects, defined as a decline in left ventricular ejection fraction (LVEF) of more than...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.